{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T09:40:19Z","timestamp":1775382019460,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.autrev.2018.03.018","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T02:36:50Z","timestamp":1534300610000},"page":"956-966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Antiphospholipid syndrome: An update on risk factors for pregnancy outcome"],"prefix":"10.1016","volume":"17","author":[{"given":"Sara","family":"De Carolis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tabacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Botta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Garufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Benedetti Panici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lanzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2018.03.018_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The European registry on obstetric antiphospholipid syndrome (EUROAPS): asurvey of 247 consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2018.03.018_bb0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1034\/j.1600-0897.2001.d01-13.x","article-title":"Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: amultivariate analysis","volume":"46","author":"Carmona","year":"2001","journal-title":"Am J Reprod Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000353633","article-title":"Long-term follow-up of intrauterine growth restriction: cardiovascular disorders","volume":"36","author":"Demicheva","year":"2014","journal-title":"Fetal Diagn Ther"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/14767058.2012.715006","article-title":"Short-term and long-term sequelae in intrauterine growth retardation (IUGR)","volume":"26","author":"Longo","year":"2013","journal-title":"J Mate-Fetal Neonatal Med"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0025","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/08035250510040223","article-title":"Long-term circulatory and renal consequences of intrauterine growth restriction","volume":"94","author":"Simeoni","year":"2005","journal-title":"Acta Paediat Int J Paediat"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.atherosclerosis.2014.09.027","article-title":"Early origins of adult disease: low birth weight and vascular remodeling","volume":"237","author":"Visentin","year":"2014","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejogrb.2003.09.040","article-title":"Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy","volume":"114","author":"Bats","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/0961203309347794","article-title":"Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome","volume":"19","author":"Bramham","year":"2010","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.autrev.2018.03.018_bb0060","article-title":"Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome","volume":"82","author":"Caruso","year":"1993","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.autrev.2018.03.018_bb0065","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: amulticentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0070","article-title":"Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome","volume":"21","author":"De Carolis","year":"2012","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1177\/0961203312447866","article-title":"The relationship between TORCH complex false positivity and obstetric outcome in patients with antiphospholipid syndrome","volume":"21","author":"De Carolis","year":"2012","journal-title":"Lupus"},{"issue":"April","key":"10.1016\/j.autrev.2018.03.018_bb0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jri.2017.08.001","article-title":"Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: amulticenter study","volume":"122","author":"Deguchi","year":"2017","journal-title":"J Reprod Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2018.03.018_bb0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/jpm-2014-0118","article-title":"Neonatal outcome in pregnant patients with antiphospholipid syndrome","volume":"43","author":"Jeremic","year":"2015","journal-title":"J Perinat Med"},{"issue":"9","key":"10.1016\/j.autrev.2018.03.018_bb0090","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0961203317692432","article-title":"Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile","volume":"26","author":"Latino","year":"2017","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/rheumatology\/kei159","article-title":"The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and\/or the antiphospholipid syndrome","volume":"45","author":"Le Thi Huong","year":"2006","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/aogs.12038","article-title":"Anti-\u03b22 glycoprotein I antibodies and pregnancy outcome in antiphospholipid syndrome","volume":"92","author":"Liu","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0105","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"August","key":"10.1016\/j.autrev.2018.03.018_bb0110","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/rheumatology\/kes225","article-title":"Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?","volume":"51","author":"Reggia","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.03.018_bb0115","first-page":"1","article-title":"Maternal and fetal outcome in women with antiphospholipid syndrome: athree-year observational study","author":"Rezk","year":"2016","journal-title":"J Mate-Fetal Neonatal Med"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0120","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.thromres.2008.03.012","article-title":"Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy","volume":"123","author":"Ruffatti","year":"2009","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acr.20098","article-title":"Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome","volume":"62","author":"Ruffatti","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.autrev.2018.03.018_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: amulticentre, case-control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.autrev.2018.03.018_bb0135","doi-asserted-by":"crossref","first-page":"525.e1","DOI":"10.1016\/j.ajog.2017.01.026","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am. J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.autrev.2018.03.018_bb0140","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1160\/TH06-01-0044","article-title":"Anti-\u03b22-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant","volume":"95","author":"Sailer","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2018.03.018_bb0145","first-page":"1428","article-title":"High Positive Antibody Titers and Adverse Pregnancy Outcome in Women with Antiphospholipid Syndrome","volume":"90","author":"Simchen","year":"2011"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1538-7836.2005.01185.x","article-title":"Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol","volume":"3","author":"Stone","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0155","first-page":"235","article-title":"Uterine artery Doppler in predicting pregnancy outcome in women with antiphospholipid syndrome","volume":"98","author":"Venkat-Raman","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.autrev.2018.03.018_bb0165","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.081194","article-title":"Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus","volume":"36","author":"Danowski","year":"2009","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0170","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0002-9378(16)32527-3","article-title":"Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant","volume":"142","author":"De Wolf","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.autrev.2018.03.018_bb0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.thromres.2004.08.005","article-title":"Antiphospholipid antibodies and fetal compromise","author":"Branch","year":"2004","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0180","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0002-9440(10)63479-7","article-title":"Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay","volume":"163","author":"Rand","year":"2003","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.autrev.2018.03.018_bb0185","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexinA5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"issue":"9133","key":"10.1016\/j.autrev.2018.03.018_bb0190","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(05)60080-3","article-title":"Action of anticardiolipin and antibodies to \u03b22-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death","volume":"352","author":"Chamley","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0378(92)90002-L","article-title":"Monoclonal antiphospholipid antibody reactivity against human placental trophoblast","volume":"22","author":"Lyden","year":"1992","journal-title":"J Reprod Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2018.03.018_bb0200","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1210\/jc.2003-032042","article-title":"Oxidized low-density lipoproteins inhibit trophoblastic cell invasion","volume":"89","author":"Pavan","year":"2004","journal-title":"J Clin Endocrinol Metabol"},{"issue":"9","key":"10.1016\/j.autrev.2018.03.018_bb0205","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00006254-200009000-00023","article-title":"Pregnancy, vascular tone, and maternal hemodynamics: acrucial adaptation","volume":"55","author":"Carbillon","year":"2000","journal-title":"Obstet Gynecol Surv"},{"issue":"5","key":"10.1016\/j.autrev.2018.03.018_bb0210","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.autrev.2015.01.008","article-title":"Histopathology in the placentae of women with antiphospholipid antibodies: asystematic review of the literature","volume":"14","author":"Viall","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0215","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/j.1600-0412.2001.800704.x","article-title":"Can uterine artery Doppler velocimetry predict adverse pregnancy outcome in women with antiphospholipid syndrome?","volume":"80","author":"Farrell","year":"2001","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"10.1016\/j.autrev.2018.03.018_bb0220","article-title":"Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity: a European multicentre retrospective study","volume":"112","author":"Ruffatti","year":"2014","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.autrev.2018.03.018_bb0225","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.thromres.2011.04.021","article-title":"Antibodies to domain I of \u03b22Glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS)","volume":"128","author":"Banzato","year":"2011","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.autrev.2018.03.018_bb0230","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1586\/1744666X.2015.1080121","article-title":"The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome","volume":"11","author":"Forastiero","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2018.03.018_bb0235","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0961203309360543","article-title":"Antiphospholipid syndrome: critical analysis of the diagnostic path","volume":"19","author":"Pengo","year":"2010","journal-title":"Lupus"},{"issue":"26","key":"10.1016\/j.autrev.2018.03.018_bb0240","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1073\/pnas.95.26.15542","article-title":"Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI","volume":"95","author":"Iverson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.autrev.2018.03.018_bb0245","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.4049\/jimmunol.169.12.7097","article-title":"Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies","volume":"169","author":"Iverson","year":"2002","journal-title":"J Immunol (Baltimore, Md. : 1950)"},{"issue":"4","key":"10.1016\/j.autrev.2018.03.018_bb0250","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis","volume":"105","author":"De Laat","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0255","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.thromres.2015.04.031","article-title":"Antibodies to domain 4\/5 (Dm4\/5) of \u03b22-glycoprotein 1 (\u03b22GP1) in different antiphospholipid (aPL) antibody profiles","volume":"136","author":"Pengo","year":"2015","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0265","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2018.03.018_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2006.10.879","article-title":"Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies","volume":"196","author":"Shamonki","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.autrev.2018.03.018_bb0275","unstructured":"Faulk, W P et al. 1980. \u201cImmunological studies of human placentae: complement components in immature and mature chorionic villi.\u201d Clin Exp Immunol 40(2): 299. file:\/\/\/pmc\/articles\/PMC1536987\/?report=abstract%5Cnpapers3:\/\/publication\/uuid\/B4348D57\u20134858-4FBB-BF59-05C05302D3F1."},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0280","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.4049\/jimmunol.151.3.1562","article-title":"Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins","volume":"151","author":"Tedesco","year":"1993","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"issue":"4","key":"10.1016\/j.autrev.2018.03.018_bb0285","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1191\/096120399678847777","article-title":"Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss","volume":"8","author":"Carbone","year":"1999","journal-title":"Lupus"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2018.03.018_bb0290","article-title":"Predictors of pregnancy outcome in antiphospholipid syndrome: areview","volume":"38","author":"De Carolis","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0295","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/jinf.2000.0670","article-title":"Systemic lupus erythematosus - is a viral Aetiology a credible hypothesis?","volume":"40","author":"Denman","year":"2000","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.autrev.2018.03.018_bb0300","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D","article-title":"Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure","volume":"44","author":"James","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2018.03.018_bb0305","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/030097401317148570","article-title":"Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus","volume":"30","author":"Nawata","year":"2001","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0090-1229(91)90086-P","article-title":"Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation","volume":"59","author":"ter Borg","year":"1991","journal-title":"Clin Immunol Immunopathol"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0315","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-37-3-559","article-title":"Systemic lupus erythematosus preceded by false-positive serologic tests for syphilis: presentation of five cases","volume":"37","author":"Haserick","year":"1952","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0320","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s100960000317","article-title":"False-positive IgM antibody tests for cytomegalovirus in patients with acute Epstein-Barr virus infection","volume":"19","author":"Miendje Deyi","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0325","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1191\/096120398678919741","article-title":"False positive IgM antibody tests for human cytomegalovirus (HCMV) in patients with SLE","volume":"7","author":"Cannavan","year":"1998","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0330","first-page":"88","article-title":"IGM antibodies against cytomegalovirus in SLE nephritis: viral infection or aspecific autoantibody?","volume":"15","author":"Stratta","year":"2002","journal-title":"J Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0335","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00430-007-0040-7","article-title":"Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity","volume":"196","author":"Su","year":"2007","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.autrev.2018.03.018_bb0340","series-title":"Association between False-Positive TORCH and Antiphospholipid Antibodies in Healthy Pregnant Women","first-page":"1","author":"De Carolis","year":"2017"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0345","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/rheumatology\/36.7.772","article-title":"Outcome of planned pregnancies in systemic lupus erythematosus: aprospective study on 62 pregnancies","volume":"36","author":"Le Huong","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"9575","key":"10.1016\/j.autrev.2018.03.018_bb0350","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: ameta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2018.03.018_bb0355","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/01.ogx.0000425641.72994.b5","article-title":"Early Administration of low-Dose Aspirin for the prevention of severe and mild preeclampsia: asystematic review and meta-analysis: editorial comment","volume":"67","author":"Roberge","year":"2012","journal-title":"Obstet Gynecol Surv"},{"issue":"Suppl(1873\u2013233X (Electronic))","key":"10.1016\/j.autrev.2018.03.018_bb0360","doi-asserted-by":"crossref","first-page":"178S","DOI":"10.1097\/01.AOG.0000447195.12926.b9","article-title":"The Medical Management of Antiphospholipid Syndrome in Pregnancy: A Meta-Analysis","volume":"123","author":"Wu","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.autrev.2018.03.018_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2017.05.006","article-title":"Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study","volume":"16","author":"Mekinian","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2018.03.018_bb0370","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.autrev.2014.08.040","article-title":"Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2018.03.018_bb0375","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.autrev.2014.12.011","article-title":"State of the art: reproduction and pregnancy in rheumatic diseases","volume":"14","author":"\u00d8stensen","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2018.03.018_bb0380","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2018.03.018_bb0385","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0037-1603359","article-title":"HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid antibodies (HYPATIA) protocol: amultinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with Antipho","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.autrev.2018.03.018_bb0400","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/0366-6999.198934","article-title":"Antiphospholipid antibody titers and clinical outcomes in patients with recurrent miscarriage and antiphospholipid antibody syndrome: a prospective study","volume":"130","author":"Song","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.autrev.2018.03.018_bb0405","first-page":"639","article-title":"Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study","volume":"118","author":"Ruffatti","year":"2018","journal-title":"Thromb Haemost"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T10:32:44Z","timestamp":1693823564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1568997218301769"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.03.018","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid syndrome: An update on risk factors for pregnancy outcome","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}